INTRODUCTION
GABA C receptors are GABA-gated chloride channels that can be distinguished from GABA A and GABA B receptors on the basis of their significant physiological, pharmacological and molecular biological differences. They are the least studied of the three major classes of GABA receptors.
The concept of GABA C receptors [1] arose out of studies on CACA (cis-4-aminocrotonic acid, Fig. 1 ), an analogue of GABA in a folded conformation [2] . The depressant action of CACA on the firing of neurones in the cat spinal cord in vivo was pharmacologically different to the main action of GABA on these neurones in that the action of CACA was insensitive to the GABA antagonist bicuculline [2] . CACA did not influence the binding of radioactive baclofen to rat brain membranes [1] and thus did not fit into the GABA A /GABA B nomenclature for GABA receptors that had been introduced in 1981 [3] . CACA was described as a 'disturber of the peace' by Krogsgaard-Larsen and colleagues [4] . This problem was solved thanks to the advent of recombinant receptor technology. The cloning of ρ1 and ρ2 cDNAs from a human retinal library enabled expression of receptors in Xenopus oocytes that showed the characteristics expected of GABA C receptors [5, 6] as did injection into oocytes of poly A + RNA from retina [7] . In 1993, studies on rat and white perch retinal cells [8, 9] revealed bicuculline-insensitive responses to both GABA and CACA, thus providing functional evidence for the existence of native GABA C responses in the retina. The rational development of the first selective GABA C receptor antagonist, TPMPA ( Fig.  1) , provided a pharmacological tool with which to probe the physiological roles of GABA C receptors [10, 11] .
Reviews of GABA C receptors have emphasised their novelty [12] , relative simplicity [13] , molecular composition [14] , role in the retina [15, 16] , structure, function and pharmacology [17, 18] , and medicinal chemistry [19, 20] . This review concentrates on GABA C receptors as targets for drug development.
GABA C RECEPTOR STRUCTURE
GABA C receptors show sequence similarity to GABA A , strychnine-sensitive glycine and nicotinic receptors, together forming part of the nicotinicoid or cys-loop superfamily of ligand gated ion channels [21] . Members of this superfamily are considered to be made up of 5 protein subunits likely to have been derived from a common ancestor [22] . The most studied and best understood of these receptors are the nicotinic acetylcholine receptors, while the GABA A receptors appear to be the most complex and the GABA C receptors the simplest.
Concepts of the overall structure of GABA C receptors are based largely on electron microscopy data for nicotinic receptors and by homology modelling with other receptors of the nicotinicoid superfamily. GABA C receptors are exceptional in that functional homomeric GABA C receptors matching wild type receptors can be formed from the same subunits, e.g. ρ1 or ρ2 subunits. Each of the five protein subunits is considered to have a large extracellular Nterminal domain which incorporates part of the agonist/antagonist binding site, followed by three membrane-spanning domains (M1-3), an intracellular loop of variable length and a fourth membrane-spanning domain (M4) with the C-terminal end being extracellular. Each subunit arranges itself such that the second membranespanning domain (M2) forms the wall of the channel pore. A cytoplasmic loop, between the third and fourth transmembrane domains (M3 and M4), is believed to be the target for protein kinases that are required for subcellular targeting and membrane clustering of the receptors.
UNIQUE PROPERTIES OF GABA C RECEPTORS
GABA C receptors can be distinguished from GABA A receptors on the basis of their different channel properties, the availability of selective agonists, antagonists and modulators, the different chromosomal localization of the genes coding for the protein subunits of the two subfamilies and the reluctance of these subunits to co-express in functional receptors, and the different proteins that anchor the protein complexes to the cytoskeleton.
The mean channel open time for GABA C receptors is greater than that of GABA A receptors. GABA C receptorgated chloride channels desensitize much less readily and are activated and closed more slowly than GABA A receptorgated chloride channels [8, 23, 24] .
(+)-CAMP ( Fig. 1) is a selective agonist at GABA C receptors being inactive at GABA A receptors [25] . No equivalent selective GABA A agonist is yet known that does not also have a significant agonist/antagonist action at GABA C receptors.
TPMPA (Fig. 1) is a selective competitive antagonist at GABA C receptors being at least 100 times more potent as an antagonist at GABA C receptors than at GABA A receptors [11] .
GABA C receptors are insensitive to the GABA A receptor positive modulators barbiturates and benzodiazepines [13] , and are only weakly positively modulated by neurosteroids [26] .
The protein subunits that can co-express to make up human recombinant GABA C receptors do not co-express with any of the human GABA A protein subunits to form functional heteromeric receptors. GABA C receptor protein subunits form functional homomeric receptors, whereas GABA A receptor protein subunits do not. Distinct GABA A and GABA C receptor responses can be observed in the same native neurones in the retina [8] and in recombinant expression systems [27] .
The genes coding for ρ1 and ρ2 GABA C subunit proteins are found on human chromosome 6 [6, 28, 29] and the gene for ρ3 is on human chromosome 3 [30] whereas the genes coding for GABA A subunit proteins show αβγ/ε clustering on human chromosomes 1, 4, 5, 15 and X. Different proteins, microtubule associated protein 1B (MAP-1B) [31] and GABA A -receptor-associated protein (GABARAP) [32] , anchor GABA C and GABA A subunits respectively to the cytoskeleton.
Phylogenetic analysis of DNA sequences indicate that the divergence of GABA C receptor subunits from GABA A receptor subunits must have occurred early in evolution [18] .
The ρ3 subtype appears to have diverged relatively early, whereas ρ1 and ρ2 subtypes appear to have diverged later [18] .
SUBTYPES OF GABA C RECEPTORS
A variety of different ρ subtypes have been cloned, including two from human retinal cDNA libraries (ρ1 and ρ2) [5, 6] with two ρ1 splice variants [33] , three from rat (ρ1-3 [34] [35] [36] [37] , two from chick (ρ1 and ρ2) [38] , five from white perch (ρ1-5 [39] , and two from mouse (ρ1 and ρ2) [40] retinae.
GABA C subtypes from all species have a conserved core primary structure that includes the proximal two-thirds of the extracellular N-terminal region and the four membrane spanning regions [18] . The least conserved regions are the distal one-third of the extracellular N-terminal domain and the intracellular loop between M3 and M4, the latter region likely to be involved in subunit specific intracellular functions such as phosphorylation and interactions with binding proteins [18] . These least conserved regions are important targets for the development of agents acting on specific GABA C receptor subtypes.
There is considerable controversy as to the exact makeup of native GABA C receptors [14, 18] . There is no doubt that ρ 1 GABA C receptor proteins can self associate into functional homomeric receptors that match the properties of native GABA C receptors in the retina. Human ρ2 and rat ρ3 GABA C receptor proteins also form functional homomeric receptors with distinct physiological and pharmacological properties. There is the possibility, however, of the formation of pseudo-homomeric receptors, e.g. ρ1ρ2, that may represent wild type receptors [41] and also of ρ GABA C receptor proteins associating with some GABA A receptor proteins in some species to form functional receptors, e.g. white perch ρ1b,γ2 [42] .
LOCALISATION OF GABA C RECEPTORS
The expression of ρ GABA C receptor subunits is not restricted to the retina with significant expression detectable in many other brain regions, especially in those belonging to the visual pathways. Wegelius et al. [43] examined the distribution of ρ1, ρ2 and ρ3 GABA C subunits and found expression of all three transcripts in several regions of the rat nervous system. With RT-PCR, expression of ρ1 was mainly seen in the adult rat retina and dorsal root ganglia as well as, at a significantly lower level, in the superior colliculus, hippocampus, brain stem and thalamus. In situ hybridization revealed expression of ρ2 in the adult rat retina and some other parts of the visual pathways. A high local ρ2 expression was seen in the superficial grey layer of the superior colliculus and in the dorsal lateral geniculate nucleus. Expression was also detected in the 6th layer of the visual cortex and in the CA1 pyramidal cell layer of the hippocampus. Expression of ρ3 mRNA was clearly different from that of ρ1 and ρ2, being strongest in the hippocampus and significantly lower in the retina, dorsal root ganglia and cortex.
Rozzo and colleagues [44] found a pattern of ρ1 and ρ2 G A B A C subunit distribution in the rat CNS more widespread than hitherto suspected. They found that in the cerebellum ρ1 and ρ2 mRNAs were expressed in Purkinje cells and basket-like cells only, while in the hippocampus they were expressed predominantly in interneurons. In the spinal cord the ρ2 signal was consistently stronger than the ρ1 signal, each showing somatodendritic localization, extending out for >100 µm with punctate appearance especially in adult cells. A similar spinal distribution pattern was provided with polyclonal antibody labelling, suggesting close correspondence between mRNA and protein compartmentalization. These studies also provided evidence for functional GABA C receptors in the rat spinal cord [44] . Studies in human CNS tissue using RT-PCR also showed a widespread expression of ρ2 mRNA whereas ρ1 expression was primarily restricted to the retina [41] . These studies, combined with electrophysiological studies on recombinant receptors, also provided evidence for pseudo-homomeric ρ1ρ2 GABA C receptors in the human retina [41] .
The expression of the three ρ GABA C receptor mRNAs in the rat gastrointestinal tract has been studied by RT-PCR indicating that GABA C receptors of differing subunit compositions are expressed by neurones in the rat gastrointestinal tract, consistent with the effects of GABA on intrinsic sensory and inhibitory motor neurones being mediated in part through GABA C receptors [45] . The ρ1 subunit was expressed in the duodenum and weakly in the colon, the ρ2 in the ileum, and the ρ3 subunit in the ileum and colon. As in the retina [46] , low concentrations of GABA may generate sustained currents through GABA C receptors, whereas GABA A receptors may mediate rapid, transient responses to GABA [45] .
There is evidence for functional GABA C receptors in the pituitary involved in thyrotropic secretion [47] and in the rat major pelvic ganglia [48] . An mRNA encoding a GABA Clike protein has been found in the heart [49] .
GABA C RECEPTOR AGONISTS AND PARTIAL AGONISTS
The archetypal GABA C ligand, CACA ( Fig. 1) , is a partial agonist for GABA C receptors, but it has other actions. It also acts on GABA transport having been shown to inhibit the uptake of β-alanine in rat brain slices [50] , to be a substrate for a transporter that transports GABA and β-alanine in glial cells from guinea pig-retina [51] and to stimulate the passive release of [ 3 H]GABA and [ 3 H]β-alanine from rat brain slices [52] . It seems likely that CACA is a substrate for the GAT-3 subtype of GABA transporter that is found in glial cells and is able to transport GABA and β-alanine. CACA is about 10 times weaker in its interactions with GABA transporters than as a partial agonist at GABA C receptors. In addition, CACA has been shown to weakly activate GABA A receptors that contain α6 subunits on rat cerebellar granule cells and on recombinant α6β2γ2 S GABA A receptors expressed in HEK cells in a bicucullinesensitive, TPMPA-insensitive manner [53] . Thus, studies using CACA as a GABA C receptor partial agonist should be interpreted with caution giving due consideration to the interaction of CACA with GABA transporters and GABA A receptors that contain α6-subunits.
TACA, the trans isomer of CACA (Fig. 2) , is the most potent GABA C receptor agonist yet described, but it is not selective as it is also a very potent GABA A receptor agonist [54, 55] . Halogeno and methyl substitutions on the C2, C3 and C4 positions of TACA reduces both the efficacy and affinity for GABA C receptors [56] . These structure-activity studies also indicate that larger substituents on the C2 position interact unfavourably with GABA C receptors. (+)-CAMP ( Fig. 1) appears to be a more selective GABA C receptor agonist than CACA [57] . Racemic CAMP has been widely investigated for its effects on a variety of GABA receptors and transporters. (±)-CAMP is a full agonist at human recombinant ρ1 and ρ2 GABA C receptors [57] and a partial agonist at rat recombinant ρ3 GABA C receptors [58] , while having no effect on [ 3 H]GABA uptake in rat brain slices [59] . Resolution of (±)-CAMP into its optical isomers, (+)-CAMP and (-)-CAMP [25] , showed that the GABA C receptor agonist activity resided in (+)-CAMP while, surprisingly, (-)-CAMP was a weak GABA C receptor antagonist [57] . It is very rare to find enantiomers exerting opposite pharmacological actions. Neither enantiomer influenced [ 3 H]GABA uptake [57] . As (±)-CAMP shows no activity at GABA A and GABA B receptors, it would appear that (+)-CAMP is the most selective GABA C receptor agonist known to date, although it has yet to be tested on α6-containing GABA A receptors.
The trans-isomers of the cyclopropane analogues of GABA show activity as partial agonists at ρ1 and ρ2 GABA C receptors with (-)-TAMP (Fig, 2) being more potent than (+)-TAMP, but both isomers also show activity as partial agonists at GABA A receptors [57] . (-)-TAMP, however, acts as an antagonist at ρ3 GABA C receptors [57] . Molecular modelling of the four cyclopropane analogues gives some insight into the chiral preferences for agonist activity at GABA C and GABA A receptors and is consistent with GABA C receptors interacting with folded conformations of GABA, as distinct from GABA A receptors interacting with extended conformations of GABA not accessible to (+)-CAMP or CACA.
The widely used GABA A agonist muscimol (Fig. 3) is a potent partial agonist at GABA C receptors [9, 27, 54, 55] . As muscimol is more potent at GABA C receptors than at G A B A A receptors, muscimol should only be used in conjunction with selective antagonists to provide information on GABA A or GABA C receptors. Muscimol at low concentrations has similar TPMPA-sensitive effects to CACA in increasing postsynaptic potentials in the rat superior colliculus while at higher concentrations muscimol attenuates these potentials acting via GABA A receptors, consistent with GABA A and GABA C receptors having contrasting effects on excitability in this tissue [60] . Interestingly, while muscimol and THIP (Fig. 3 ) , a conformationally restricted analogue of muscimol [61] , have similar actions as agonists at GABA A receptors, THIP is an antagonist at GABA C receptors [27, 58] . Isoguvacine (Fig.  3) acts as a GABA A receptor agonist and a GABA C receptor partial agonist, the latter activity being important in the design and development of TPMPA as a selective GABA C receptor antagonist [10, 11] . The effects of an anxiolytic honokiol derivative, dihydrohonokiol-B (Fig. 4) , on ammonia-induced increases in the intracellular chloride ion concentration in cultured hippocampal neurones could be blocked by the GABA C receptor antagonist TPMPA and mimicked by CACA, indicating that dihydrohonokiol-B might directly activate GABA C receptors [62] .
GABA C RECEPTOR ANTAGONISTS
The rational design and development of TPMPA (Fig, 1) as the first selective GABA C receptor antagonist resulted from considerations of agents that acted only on GABA A and GABA C receptors (such as isoguvacine, Fig. 3) , and those that acted only on GABA B and GABA C receptors (such as 3-APMPA, Fig. 5 ) [10, 11] . Reasoning that the tetrahydropyridine ring of isoguvacine was unfavourable for interactions with GABA B receptors, while the methylphosphinic moiety of 3-APMPA was unfavourable for interactions with GABA A receptors led to the synthesis of TPMPA which incorporates both the tetrahydropyridine and methylphosphinic acid moieties in the one compound. TPMPA did indeed prove to be selective for GABA C receptors. TPMPA has been used to provide evidence of functional GABA C receptors in the rat superior colliculus mediating disinhibition [63] , in cells in the gut involved in neuroendocrine secretion [64] and in rat spinal cord [65] . TPMPA has been shown to enhance memory in chicks on intracranial injection [66] . Phosphinic, phosphonic and seleninic bioisosteres of isonipecotic acid (Fig. 5) are selective GABA C receptor antagonists [66] [67] [68] . P4MPA, the piperidine analogue of TPMPA, was a more potent antagonist than was TPMPA at human recombinant ρ2 GABA C receptors, but weaker at human recombinant ρ1 and rat recombinant ρ3 GABA C receptors [58] . Piperidin-4-ylphosphinic acid (PPA) was comparable with TPMPA in terms of potency and selectivity for GABA C over GABA A receptors. The corresponding seleninic acid, piperidine-4-ylseleninic acid (SEPI), was more potent than TPMPA, showed a higher selectivity for ρ1 GABA C receptors relative to GABA A receptors than TPMPA and was inactive at GABA B receptors [68, 69] . CGP36742, 3-aminopropyl-n-butylphosphinic acid (Fig.  5) , was developed as an orally active GABA B receptor antagonist [70, 71] . Functional studies on ρ1 GABA C receptors expressed in oocytes showed however that CGP36742 acted as a GABA C receptor antagonist with a potency approximately half that displayed against GABA B receptors [72] . CGP36742 has shown promising therapeutic potential for the treatment of cognitive deficits [73, 74] . As not all orally active GABA B antagonists show this therapeutic potential [71] , it is possible that antagonism of GABA C receptors contributes to these effects [66, 72] . It would be useful to have an analogue of CGP36742 that was a selective GABA C receptor antagonist with no activity on GABA B receptors in order to determine the extent to which GABA C receptor antagonism contributes to the cognitive enhancing effects of CGP36742. THIP (Fig. 3) is a conformationally restricted analog of muscimol. It is a potent GABA A receptor partial agonist of high efficacy [61] but has proved to be a moderately potent antagonist at GABA C receptors [27] particularly at rat ρ3 GABA C receptors [58] . THIP is a potent analgesic on systemic administration [4] but side effects (including sedation, dizziness, and blurred vision) meant that it had too low a therapeutic index to be therapeutically useful as an analgesic [75, 76] . THIP-induced analgesia is not sensitive to bicuculline indicating that GABA A receptors are not involved [77] . It is possible that the GABA C receptor antagonist action of THIP contributes to its analgesic action.
THIP shows potential in sleep therapy as it produces slow wave sleep and reduces spindling activity in non rapid eye movement sleep in humans [78] . The effects of THIP on sleep patterns do not appear to involve benzodiazepinesensitive GABA A receptors [78] . As a result of studies using the GABA C receptor antagonist TPMPA, GABA C receptors are known to be involved in sleep-waking behaviour [79] .
Several analogs of THIP have been examined for their actions on GABA A and GABA C receptors (D Krehan, B. Frølund, P Krogsgaard-Larsen, GAR Johnston and M Chebib, unpublished observations). Of particular interest in the current context are those analogs showing selectivity for GABA C receptors. Aza-THIP (Fig. 6) is a competitive antagonist (Ki 31 µM) at human recombinant ρ1 GABA C receptors that does not interact detectably with GABA A receptors (IC50 > 100 µM). N-Methylation of aza-THIP at positions 1 or 2 yielded compounds inactive at both GABA A and GABA C receptors. Iso-THIP is a more potent GABA C antagonist (Ki 7.9 µM) than either THIP (Ki 20 µM) or aza-THIP, but shows some activity against GABA A receptor binding (IC50 83 µM). Aza-THIP may be a useful compound for behavioural and pharmacological studies to assess those effects of THIP that may be due to its GABA C antagonist properties. 2-Methyl-TACA (Fig. 2) is a competitive antagonist at human ρ1 GABA C receptors and a partial agonist at human ρ2 receptors and thus may be useful in differentiating native homomeric ρ1 and ρ2 receptors in tissues [80] . (+)-4-ACPCA (Fig. 2) , a cyclised form of 2-methyl-TACA, is a more potent GABA C antagonist than 2-methyl-TACA, but does not distinguish between ρ1 and ρ2 GABA C receptors [81] .
4-(Aminomethyl)-2,6-difluorophenol (Fig, 4 ) is representative of a novel class of GABA C receptor antagonists with increased lipophilicity designed to penetrate the blood brain barrier [82] . It is a competitive antagonist at human recombinant ρ1 GABA C receptors with little activity at GABA A and GABA B receptors. It is one of a number of phenols that influence GABA C receptors, in this case with a 2,6-difluorophenol moiety acting as a bioisostere for a carboxylic acid group.
Among many other actions, imidazole-4-acetic acid has an affinity for GABA C receptors where it seems to act as an antagonist and perhaps as a weak partial agonist [83] .
Antibodies raised against the N-terminal domain of ρ1 GABA C receptor protein have been shown to antagonise ρ1 GABA C receptors expressed in oocytes [84] .
ALLOSTERIC MODULATION OF GABA C RECEPTORS
Agents that influence the activation of GABA C receptors by GABA by acting at sites distinct from the GABA recognition sites are called allosteric modulators. In general, allosteric modulators are important novel targets for drug discovery offering the increased likelihood of subtypeselectivity as there is greater divergence between receptor subtypes in sequence homology in domains that define allosteric sites than in domains that interact with the endogenous agonist [85] . Non-competitive antagonists of the activation of GABA C receptors by GABA, e.g. picrotoxinin, are generally considered to be negative allosteric modulators, whereas agents that enhance, e.g. allopregnanolone at µM concentrations, are called positive allosteric modulators.
Rodent GABA C receptors are relatively resistant to negative modulation by picrotoxinin [8] . This appears to be due to a single mutation (threonine to methionine) in the M2 region of rat ρ1 GABA C receptors [86] . As rat ρ2 GABA C receptors do not form functional homomeric receptors, this suggests that the subunit composition of native rat GABA C receptors is heteromeric, comprising ρ1 and ρ2 subunits [18] . Picrotoxinin is a use-dependent negative modulator of GABA C receptors indicating that the modulatory site is probably inside the receptor, access by picrotoxinin requiring GABA to be bound to the receptor [87] .
Loreclezole (Fig. 7 ) , a potent positive allosteric modulator of GABA A receptors containing a β2 or β3 subunit but not a β1 subunit [88] , is a negative modulator of ρ1 GABA C receptors providing a simple functional marker for these receptors [89] . (+)-ROD188 (Fig. 7) is also a positive modulator of GABA A receptors [90, 91] and a negative modulator of GABA C receptors, but with a different mode of action to loreclezole [89] . Human homomeric ρ1 GABA C receptors show a unique specificity to insecticides [92] . Relative to GABA A receptors, these GABA C receptors were much more sensitive to lindane (Fig. 7) than any other chlorinated insecticide and were essentially insensitive to fipronil. As these authors note: 'All commercial insecticides are carefully studied for ocular toxicity which is not reported to be a problem with any of the major compounds discussed here consistent with their relatively low potency at the ρ1 GABA C receptor.' [92] .
Resveratrol (Fig. 4) is a moderately potent GABA C receptor non-competitive antagonist (IC50 72 µM) [93] . Resveratrol is an important constituent of red wine and has been patented for the treatment of mild cognitive disorders [94] .
Divalent cations differentially modulate GABA C receptors. While Ca 2+ acts as a positive modulator, other divalent cations act as negative modulators in the following order of the potency: Zn 2+ > Ni 2+ > Cd 2+ > Co 2+ [95] . The negative modulation of GABA C receptors by Zn 2+ is not use-dependent suggesting that it binds to a site on the extracellular portion of these receptors [87] .
Lanthanide cations are positive modulators of GABA C receptors. Their order of potency is Lu 3+ > Eu 3+ > Tb 3+ > Gd 3+ > Er 3+ > Nd 3+ > La 3+ > Ce 3+ . La 3+ ions enhance with an EC50 of 135 µM and an Emax of 100% at 1mM vs. 1 µM GABA, but the effects are not specific with La 3 + having a similar action on GABA A receptors [96] .
While there is an extensive literature on the positive modulation of GABA A receptors by a variety of agents, GABA C receptors appear to be little influenced by these agents [19] . This was thought to be due to the simpler homomeric structure of GABA C receptors offering less opportunity for positive modulation. The more complex heteromeric GABA A receptors were considered to represent an adaptation offering increased opportunities for modulatory effects perhaps as a trade-off for being less sensitive to activation by GABA in the absence of positive modulators than GABA C receptors [13] .
While early studies reported GABA C receptors to be insensitive to modulation by neuroactive steroids under conditions where such steroids at nM concentrations modulated GABA A receptors [97] , it is now known that higher concentrations (i.e. µM) of steroids can modulate G A B A C receptors [26] . The low affinity effects of neuroactive steroids on GABA C receptors are more apparent at low concentrations of GABA well below its EC50. Under such conditions, the anaesthetic agent alphaxalone and the neurosteroids allopregnanolone and allotetrahydrodeoxycorticosterone (5α-THDOC) (Fig. 8) enhanced GABAevoked currents at ρ1 GABA C receptors expressed in oocytes and prolonged the decay time of these currents, i.e. they were positive modulators. At 20 µM, these steroids potentiated GABA-evoked currents by 96%, 42% and 198% respectively. These are all 5α-steroids and are the first examples of agents able to positively modulate GABA C receptors. Their actions are not specific as each of them positively modulates GABA A receptors at nM concentrations.
The related β-steroids -5β-dihydroprogesterone (IC50 5 µM), pregnanolone (IC50 0.55 µM) and tetrahydrodeoxycorticosterone (5β-THDOC, IC50 1 µM) -were negative modulators in that they reduced GABAevoked currents at these ρ1 GABA C receptors [26] . Thus the configuration of the A/B ring junction in these steroids influences their action on GABA C receptors, the transconfiguration in the 5α -steroids being favourable to enhancing GABA action and the cis-configuration resulting in inhibition of GABA action. The low affinity effects of these neuroactive steroids on GABA C receptors are quite different from the high affinity effects typically observed with GABA A receptors [26] .
Mutations in GABA C receptors do result in receptors susceptible to positive modulation. Thus a single mutation in the M2 region of ρ1 GABA C receptors yields receptors that can be positively modulated by pentobarbitone but not by the general anaesthetic propofol or the neuroactive steroid 5β-pregnan-3α-ol-20-one [98] . This mutation involved replacing the ρ1 wild type GABA C leucine at position 307 with serine, the homologous amino acid in GABA A receptor α1-6, β1 and γ1-3 subunits. A single mutation in the TM3 region of ρ1 GABA C receptors (tryptophan 328 mutated to a range of hydrophobic amino acids) also results in positive modulation by barbiturates [99] . Thus positions 307 (M2) and 328 (M3) are of interest with respect to modulation of ρ1 GABA C receptors. Wild type GABA C receptors are insensitive to benzodiazepines, but mutations in the TM2 and TM3 regions can confer low affinity benzodiazepine sensitivity to ρ1 GABA C receptors [100] .
Anchoring ρ1 GABA C receptors in the retina to the cytoskeleton with the protein MAP1B lowers the sensitivity of GABA C receptors and provides a likely site for functional modulation of GABA C receptor-mediated inhibition [101] . Another site is protein kinase C which has been shown to be involved in surface expression of GABA C receptors in recombinant systems [102] .
GABA C RECEPTOR GENE THERAPY
The introduction of exogenous GABA C receptors via adenovirus transduction is a possible alternative therapy to conventional drug therapy that influences the activity of endogenous GABA C receptors. Such gene therapy offers the ability to target neurones in particular brain regions. Cheng et al. [103] transduced hippocampal neurones in culture with an adenovirus vector that expressed cDNA for ρ1 GABA C receptors and a green fluorescence protein reporter. This led to the expression of functional GABA C receptors that resulted in the elimination of neuronal hyperexcitability and delayed neuronal death induced by chronic blockade of glutamate receptors. Filippova et al. [104] infected human embryonic kidney cells, human embryonic retinal cells, and dissociated and cultured rat hippocampal neurones with a recombinant adenovirus containing the human ρ1 GABA C receptor. They showed functional GABA C receptors to be present in each of these preparations, concluding that 'the high infection capabilities of adeno-ρ with respect to hippocampal neurones opens the way for gene therapy treatment of CNS-related diseases such as epilepsy'. They also speculate on 'the use of custom-made ρ1 mutant with preferred properties'.
There are differences between the two adenovirus studies. Cheng et al. [103] found an increased expression of GABA A receptors after infection with the GABA C virus, while Filippova et al. [104] found a decrease. Possible differences in the two methodologies include the choice of promoters and expression vectors.
GABA C ρ ρ ρ ρ1 KNOCKOUT MICE
McCall et al. [105] have shown that elimination of the ρ1 GABA C subunit in mice abolishes GABA C receptor expression in the retina and alters visual processing. In these ρ1 null mice, GABA C receptor mediated responses in the retina and signalling from rod bipolar cells to third order cells was altered. The authors attributed the lack of expression of ρ2 GABA C subunits to an alteration in ρ2 gene expression upstream of the ρ1 gene deletion or to alterations in the assembly or targeting of functional GABA C receptors in vivo. They found no evidence of GABA C receptors playing a role in retinal development with the ρ1 null mice showing normal retinal morphology. This is consistent with evidence that GABA C receptors do not contribute to excitatory GABA responses and related calcium signals in neonatal neurones [106] . No overt behavioural or physical changes were reported. Given the more widespread distribution of ρ2 GABA C receptors in the CNS and their possible association with cognition and sleep disorders, it would be interesting to study ρ2 null mice.
INDICATIONS FOR DRUGS ACTING ON GABA C RECEPTORS
At the present time, the major indications for drugs acting on GABA C receptors are in the treatment of visual, sleep and cognitive disorders, all possibly involving GABA C receptors in visual and related systems. Given the lower abundance and less widespread distribution of GABA C receptors in the CNS compared to GABA A receptors, GABA C receptors may be a more selective drug target than GABA A receptors. As distinct from GABA A receptors, there is little evidence for the involvement of GABA C receptors in mood or motor function with no reported effects of selective GABA C receptor agents having anxiolytic, anxiogenic, anticonvulsant or convulsant properties.
As ρ1 GABA C receptors are found in their highest numbers in the retina, it would be expected that retinal dysfunction would be a major therapeutic target for drugs acting on these receptors. Genetic linkage and radiation hybrid mapping show that the human genes coding for ρ1 and ρ2 GABA C receptors are located close together, in a region of chromosome 6q that contains loci for inherited disorders of the eye [30] including autosomal recessive retinitis pigmentosa [107] .
The effects of the GABA C receptor antagonists TPMPA and THIP on sleep suggest that GABA C receptor based therapy may be useful in the treatment of sleep disorders [79, 108] . Gottesmann has recently reviewed GABA A mechanisms in sleep [109] . The analgesic effects of THIP are insensitive to the GABA A antagonist bicuculline [77] and thus these effects may involve GABA C receptor antagonism although there is as yet no direct evidence for this [20] .
GABA C receptor antagonists (TPMPA, CGP36742, resveratrol) have been shown to enhance cognition and thus may have application in the treatment of memory disorders associated with Alzheimer's disease and schizophrenia [66, 67, 94] .
